Home > Gastroenterology > DCF outperforms standard-of-care for locally advanced oesophageal cancer

DCF outperforms standard-of-care for locally advanced oesophageal cancer

Presented By
Dr Ken Kato, National Cancer Center Hospital, Japan

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASCO GI 2022
Trial
Phase 3, JCOG1109, NExT
Docetaxel plus neoadjuvant cisplatin and 5-fluorouracil (DCF) chemotherapy was superior to CF chemotherapy alone in patients with locally advanced oesophageal cancer, according to the primary analysis of the phase 3 JCOG1109 NExT trial. Moreover, the toxicity profile of the DCF combination regimen was manageable. Therefore, neoadjuvant DCF represents a potential new standard therapy for this Japanese patient population [1]. “In Japan, neoadjuvant chemotherapy with CF is the standard-of-care in locally advanced oesophageal cancer,” Dr Ken Kato (National Cancer Center Hospital, Japan) explained. The current 3-arm, randomised-controlled, phase 3 JCOG1109 trial (UMIN000009482) compared neoadjuvant DCF with neoadjuvant CF and neoadjuvant CF with radiotherapy (CF-RT). In total, 601 patients were rando...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on